Geode Capital Management LLC Has $10.70 Million Stock Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

Geode Capital Management LLC boosted its position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) by 6.2% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 813,489 shares of the company’s stock after acquiring an additional 47,846 shares during the quarter. Geode Capital Management LLC’s holdings in Y-mAbs Therapeutics were worth $10,699,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently bought and sold shares of the company. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in Y-mAbs Therapeutics during the third quarter valued at about $44,000. China Universal Asset Management Co. Ltd. lifted its position in shares of Y-mAbs Therapeutics by 66.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,572 shares of the company’s stock worth $113,000 after purchasing an additional 3,416 shares during the last quarter. Intech Investment Management LLC bought a new stake in Y-mAbs Therapeutics during the 3rd quarter valued at approximately $133,000. SG Americas Securities LLC acquired a new stake in Y-mAbs Therapeutics in the 3rd quarter valued at approximately $178,000. Finally, Principal Financial Group Inc. bought a new position in Y-mAbs Therapeutics in the 3rd quarter worth approximately $267,000. Institutional investors own 70.85% of the company’s stock.

Y-mAbs Therapeutics Stock Up 0.9 %

Shares of YMAB opened at $7.83 on Wednesday. The company has a 50-day moving average price of $11.45 and a two-hundred day moving average price of $12.37. The stock has a market cap of $350.70 million, a price-to-earnings ratio of -14.50 and a beta of 0.61. Y-mAbs Therapeutics, Inc. has a 12 month low of $6.48 and a 12 month high of $20.90.

Y-mAbs Therapeutics (NASDAQ:YMAB) last posted its earnings results on Friday, November 8th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.02). Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. The company had revenue of $18.46 million for the quarter, compared to the consensus estimate of $23.38 million. During the same quarter last year, the business earned ($0.18) EPS. Equities research analysts expect that Y-mAbs Therapeutics, Inc. will post -0.66 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages have recently issued reports on YMAB. Brookline Capital Management started coverage on shares of Y-mAbs Therapeutics in a research note on Thursday, December 5th. They issued a “buy” rating and a $17.00 price objective on the stock. Cantor Fitzgerald restated an “overweight” rating and issued a $20.00 price target on shares of Y-mAbs Therapeutics in a research report on Monday, September 9th. HC Wainwright restated a “buy” rating on shares of Y-mAbs Therapeutics in a report on Wednesday, December 11th. Oppenheimer assumed coverage on shares of Y-mAbs Therapeutics in a research note on Monday, November 18th. They issued an “outperform” rating and a $23.00 target price for the company. Finally, Wedbush restated an “outperform” rating and set a $23.00 price target on shares of Y-mAbs Therapeutics in a research note on Tuesday, September 10th. One equities research analyst has rated the stock with a sell rating, seven have assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $20.89.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.